CN112384243A - 三价三特异性抗体构建体 - Google Patents

三价三特异性抗体构建体 Download PDF

Info

Publication number
CN112384243A
CN112384243A CN201980040529.7A CN201980040529A CN112384243A CN 112384243 A CN112384243 A CN 112384243A CN 201980040529 A CN201980040529 A CN 201980040529A CN 112384243 A CN112384243 A CN 112384243A
Authority
CN
China
Prior art keywords
domain
amino acid
sequence
acid sequence
polypeptide chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980040529.7A
Other languages
English (en)
Chinese (zh)
Inventor
L·贝利
B·格拉泽
李曲飞
R·格林
D·K·普鲁库纳特
M·A·诺库拉-鲁格维斯卡
D·J·格哈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invenra Inc
Original Assignee
Invenra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invenra Inc filed Critical Invenra Inc
Publication of CN112384243A publication Critical patent/CN112384243A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980040529.7A 2018-04-17 2019-04-17 三价三特异性抗体构建体 Pending CN112384243A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659047P 2018-04-17 2018-04-17
US62/659,047 2018-04-17
PCT/US2019/027816 WO2019204398A1 (en) 2018-04-17 2019-04-17 Trivalent trispecific antibody constructs

Publications (1)

Publication Number Publication Date
CN112384243A true CN112384243A (zh) 2021-02-19

Family

ID=68240367

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980040529.7A Pending CN112384243A (zh) 2018-04-17 2019-04-17 三价三特异性抗体构建体

Country Status (10)

Country Link
US (2) US20210179734A1 (enExample)
JP (1) JP2021521781A (enExample)
KR (1) KR20200143730A (enExample)
CN (1) CN112384243A (enExample)
AU (1) AU2019255270A1 (enExample)
BR (1) BR112020021279A2 (enExample)
CA (1) CA3097605A1 (enExample)
IL (1) IL278073A (enExample)
MX (1) MX2020011027A (enExample)
WO (1) WO2019204398A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348603B (zh) * 2015-11-03 2023-12-29 Ambrx公司 抗cd3叶酸结合物和其用途
DK3529269T3 (da) * 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
AU2021304372A1 (en) * 2020-07-10 2023-03-02 Biomolecular Holdings Llc Tetrahedral antibodies
US20240228588A1 (en) * 2021-01-11 2024-07-11 Adimab, Llc Variant ch1 domains and variant cl domains engineered for preferential chain pairing and multi-specific antibodies comprising the same
AU2022215712A1 (en) * 2021-02-07 2023-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
TW202506725A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 三特異性工程化抗體
EP4702058A2 (en) * 2023-04-28 2026-03-04 Xencor, Inc. Orthogonal multimeric proteins
EP4777539A1 (en) * 2023-09-11 2026-07-22 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN104936986A (zh) * 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
WO2016079081A1 (en) * 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
CN106414497A (zh) * 2014-05-29 2017-02-15 宏观基因有限公司 三特异性结合分子和其使用方法
WO2017055391A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
CN107206072A (zh) * 2014-11-20 2017-09-26 豪夫迈·罗氏有限公司 T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD‑1轴结合拮抗剂的组合疗法
WO2017180913A2 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
SG10202107077QA (en) * 2014-04-02 2021-07-29 Hoffmann La Roche Method for detecting multispecific antibody light chain mispairing
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
JP7021955B2 (ja) * 2015-06-24 2022-03-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN109069633A (zh) * 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN104936986A (zh) * 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
CN106414497A (zh) * 2014-05-29 2017-02-15 宏观基因有限公司 三特异性结合分子和其使用方法
WO2016079081A1 (en) * 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
CN107207609A (zh) * 2014-11-20 2017-09-26 豪夫迈·罗氏有限公司 共同轻链和使用方法
CN107206072A (zh) * 2014-11-20 2017-09-26 豪夫迈·罗氏有限公司 T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD‑1轴结合拮抗剂的组合疗法
WO2017055391A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
WO2017180913A2 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN KLEIN ET AL.: "The use of CrossMAb technology for the generation of bi- and multispecific antibodies", vol. 8, no. 6, pages 1011 - 1 *
XIUFENG WU ET AL.: "Generation of orthogonal Fab-based trispecific antibody formats", PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 31, no. 7, pages 249 - 256, XP055865763, DOI: 10.1093/protein/gzy007 *

Also Published As

Publication number Publication date
JP2021521781A (ja) 2021-08-30
WO2019204398A1 (en) 2019-10-24
BR112020021279A2 (pt) 2021-04-13
KR20200143730A (ko) 2020-12-24
EP3781205A1 (en) 2021-02-24
CA3097605A1 (en) 2019-10-24
AU2019255270A1 (en) 2020-11-19
IL278073A (en) 2020-11-30
US20250026861A1 (en) 2025-01-23
US20210179734A1 (en) 2021-06-17
MX2020011027A (es) 2021-01-15

Similar Documents

Publication Publication Date Title
JP7591015B2 (ja) 抗体構築物
US20250026861A1 (en) Trivalent trispecific antibody constructs
US20240392002A1 (en) Anti-ror antibody constructs
US20210163594A1 (en) Binding molecules
US20220213225A1 (en) Multispecific treg binding molecules
CA3210307A1 (en) Bispecific antibody
US20210363265A1 (en) Multivalent receptor-clustering agonist antibody constructs
US20220153844A1 (en) Multispecific treg binding molecules
CN114340737B (zh) 激活性抗gal9结合分子
WO2019183406A1 (en) Multispecific antibody purification with ch1 resin
EA048615B1 (ru) Конструкции антител к ror

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210219